Librela (bedinvetmab) is a medication that many veterinarians use to help dogs with osteoarthritis (arthritis) pain. It works differently than traditional pain medications because it blocks a protein called nerve growth factor (NGF), which helps transmit pain signals.

Recently, a citizen petition was submitted to the U.S. Food and Drug Administration (FDA) asking the agency to take a closer look at the long-term safety of Librela and consider adding stronger safety requirements.

What Is a Citizen Petition?

A citizen petition is a formal request asking the FDA to review a concern and consider regulatory action. It does not mean the FDA has agreed with the concerns or made any decisions. It simply starts a process where the FDA reviews the information that was submitted.

The petition was filed by the Pharmaceutical Safety Oversight Council (PSOC) on June 1, 2026. The group states that it is not asking for Librela to be immediately removed from the market. Instead, it is asking for additional safety studies, stronger warnings, and more monitoring of dogs receiving the medication.

What Concerns Were Raised?

The petition focuses on reports of neurologic and musculoskeletal problems in some dogs receiving Librela. Examples discussed include:

• Weakness
• Trouble walking (ataxia)
• Knuckling or proprioceptive deficits
• Seizures
• Collapse
• Paralysis
• Rapid worsening of arthritis or joint damage

The petition also points to FDA adverse event reports and published veterinary literature discussing these concerns.

According to the petition, the FDA’s adverse event database contained more than 16,000 reports associated with Librela as of December 31, 2025. The petition notes that adverse event reports alone cannot prove that a medication caused a problem, but they can help identify safety signals that deserve further investigation.

What Is the Petition Asking the FDA To Do?

The petition requests several actions, including:

• Additional long-term safety studies
• Stronger warning labels
• Neurologic evaluations before and during treatment
• Better owner education about potential risks
• More detailed adverse event reporting
• An independent advisory committee review of Librela’s safety data
• Creation of a public FDA resource dedicated to Librela safety information

The petition argues that these steps could help veterinarians and pet owners make more informed treatment decisions.

Why Is NGF Important?

One of the main arguments in the petition is that NGF does more than just transmit pain signals. The document discusses research suggesting NGF may also play roles in:

• Nerve health
• Brain function
• Bone repair
• Joint remodeling
• Healing after injury

The petition argues that because Librela blocks NGF, additional research is needed to better understand the long-term effects of this pathway in older dogs.

What Does This Mean for Dog Owners?

At this time, Librela remains FDA-approved and available for use in dogs with osteoarthritis pain.

Many dogs have experienced meaningful improvement in comfort and mobility while receiving Librela. However, concerns have been raised by veterinarians, researchers, pet owners, and regulators regarding potential adverse effects, particularly neurologic changes and rapidly progressive osteoarthritis (RPOA).

If your dog is receiving Librela, it is important to monitor for any new symptoms, including:

• Weakness
• Knuckling
• Difficulty standing
• Changes in coordination
• Seizures
• Sudden worsening of lameness
• Significant behavior changes

Any concerns should be discussed with your veterinarian as soon as possible.

My Take

Librela has helped many dogs with arthritis pain, and it fills an important need for patients that cannot tolerate traditional anti-inflammatory medications. At the same time, veterinarians should continue to carefully monitor patients and report suspected adverse events.

The questions raised in this citizen petition deserve scientific investigation. More long-term safety data, better understanding of which patients may be at higher risk, and continued transparency from regulators will help veterinarians and pet owners make the best decisions for individual dogs.

Importantly, the filing of a citizen petition does not prove that Librela is unsafe. It is a request for the FDA to review the available evidence and determine whether additional safeguards are needed.

Learn More

FDA Citizen Petition (FDA-2026-P-6249):
FDA Citizen Petition Docket

FDA Center for Veterinary Medicine Electronic Reading Room (adverse event reports):
FDA CVM Electronic Reading Room

FDA Dear Veterinarian Letter on Librela:
Available through the FDA CVM website and linked within the Electronic Reading Room resources.